Kadmon Holdings, Inc.: Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

- REZUROCK (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third

Related Keywords

United States ,American ,Harlanw Waksal , ,American Society Of Hematology ,Exchange Commission ,Society For Immunotherapy Of Cancer ,Kadmon Holdings Inc ,Nasdaq ,Program Updates ,Kadmon Holdings ,General Medicines ,Kadmon Boards ,American Society ,Annual Meeting ,Investigational New Drug Application ,Capital Resources ,Orphan Drug Designation ,Fetal Toxicity ,Prescribing Information ,Investor Relations ,Annual Report ,Private Securities Litigation Reform Act ,Consolidated Balance Sheets ,Kadmon ,Oldings ,Rovides ,Business ,Update ,Reports ,Third ,Quarter ,021 ,Financial ,Results ,